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We recently reported that a neurosteroid analogue with T-channel-blocking properties
(3β,5β,17β)-3-hydroxyandrostane-17-carbonitrile (3β-OH), induced hypnosis in rat pups
without triggering neuronal apoptosis. Furthermore, we found that the inhibition of the
CaV3.1 isoform of T-channels contributes to the hypnotic properties of 3β-OH in adult mice.
However, the speciﬁc mechanisms underlying the role of other subtypes of voltage-gated
calcium channels in thalamocortical excitability and oscillations in vivo during 3β-OH-induced
hypnosis are largely unknown. Here, we used patch-clamp recordings from acute brain slices, in
vivo electroencephalogram (EEG) recordings, and mouse genetics with wild-type (WT) and
CaV2.3 knock-out (KO) mice to further investigate the molecular mechanisms of neurosteroidinduced hypnosis. Our voltage-clamp recordings showed that 3β-OH inhibited recombinant
CaV2.3 currents. In subsequent current-clamp recordings in thalamic slices ex vivo, we found
that selective CaV2.3 channel blocker (SNX-482) inhibited stimulated tonic ﬁring and increased
the threshold for rebound burst ﬁring in WT animals. Additionally, in thalamic slices we found that
3β-OH inhibited spike-ﬁring more profoundly in WT than in mutant mice. Furthermore, 3β-OH
reduced bursting frequencies in WT but not mutant animals. In ensuing in vivo experiments, we
found that intra-peritoneal injections of 3β-OH were less effective in inducing LORR in the mutant
mice than in the WT mice, with expected sex differences. Furthermore, the reduction in total α, β,
and low γ EEG power was more profound in WT than in CaV2.3 KO females over time, while at
60 min after injections of 3β-OH, the increase in relative β power was higher in mutant females. In
addition, 3β-OH depressed EEG power more strongly in the male WT than in the mutant mice
and signiﬁcantly increased the relative δ power oscillations in WT male mice in comparison to the
mutant male animals. Our results demonstrate for the ﬁrst time the importance of the CaV2.3
subtype of voltage-gated calcium channels in thalamocortical excitability and the oscillations that
underlie neurosteroid-induced hypnosis.
Keywords: voltage-gated calcium channels, R-type calcium channels, hypnosis, EEG, neuroactive steroids,
thalamus, ex vivo in slice electrophysiology
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INTRODUCTION

the CaV2.3 channels are encoded by the cacna1e gene and
expressed in different splice variants in the brain (Williams
et al., 1994; Schneider et al., 2020). It is well known that R-type
channels are modulated by protein phosphorylation
(Neumaier et al., 2018; Schneider et al., 2018), glutamate
and trace metals such as Zn 2+ and Cu2+ (Shcheglovitov
et al., 2012; Neumaier et al., 2020), and G protein-coupled
receptors (GPCRs) (Berecki et al., 2016; Jeong et al., 2016).
The R-type channel is also known to play a role in
epileptogenesis in rodents, and its deletion reduces
susceptibility to chemically induced seizures (Weiergräber
et al., 2006, 2007; Zaman et al., 2011; Simms and Zamponi,
2014; Helbig et al., 2018). Changes in the expression of CaV2.3
channels were also reported in Parkinson’s disease (Benkert
et al., 2019; Schneider et al., 2020) and pain processing
(Saegusa et al., 2000, 2002). Importantly, we showed that
CaV2.3 channels are important molecular target for the
effects of the volatile anesthetic isoﬂurane in the TRN
(Joksovic et al., 2009). Additionally, CaV2.3-deﬁcient mice
exhibited reduced wake duration (spontaneous or urethaneinduced), increased slow-wave sleep (SWS), changes in sleep
stage transitions, and altered electroencephalographic (EEG)
amplitudes (Siwek et al., 2014). Previous molecular studies
have demonstrated that CaV2.3 calcium channels are
abundantly expressed in the brain, with relatively low
expression in thalamocortical projection neurons (Williams
et al., 1994; Parajuli et al., 2012) and a higher expression in
GABAergic interneurons of the TRN (Weiergräber et al.,
2008). However, since the inhibitory TRN projects to the
majority of thalamic nuclei (Scheibel and Scheibel, 1966;
Steriade et al., 1984; Kolmac and Mitrofanis, 1997), it is
reasonable to infer that the global deletion of R-type
channels may alter excitability across the whole thalamus.
The central medial nucleus of thalamus (CMT) is a part of the
intralaminar thalamus with diffuse projections to the anterior
and posterior regions of the cortex, the nucleus accumbens,
claustrum, the caudate-putamen, the olfactory tubercle, and
the amygdala (Vertes et al., 2012). It has been proposed that
CMT acts as a key hub through which general anesthesia and
natural sleep are initiated (Baker et al., 2014).
Here, we used in vitro (recordings from HEK cells) and ex
vivo (CMT slices recordings) molecular studies with qPCR and
in vivo EEG electrophysiology with behavioral testing to
investigate the possible role of CaV2.3 R-channels in the
hypnotic effect of 3β-OH in mice. We already demonstrated
dose-dependent sex differences in 3β-OH-induced hypnosis
and EEG changes in rats (Joksimovic et al., 2021), and
consequently investigated sex-dependent neurosteroid
effects using mouse genetics in this study.

The mechanisms whereby general anesthetics produce a loss of
consciousness are not well understood, but it is well known
that most general anesthetics currently in use have either
N-methyl-D-aspartate (NMDA) receptor-blocking and/or γaminobutyric acid A (GABAA) receptor-enhancing properties.
The idea that neuroactive steroids have sedative/hypnotic
properties has been around since the introduction of
alphaxalone ((3α,5α)3-hydroxypregnane-11,20-dione) (Lau
et al., 2013; Arenillas and Gomez de Segura, 2018). Many
neuroactive steroids act as positive modulators of GABAA
receptors and can be effective modulators of other receptors
(serotonin, NMDA, α2-adrenergic) or voltage-gated calcium
(L- and T-type) ion channels (Lambert et al., 1995; Rupprecht,
2003; Stell et al., 2003; Belelli and Lambert, 2005; Tuem and
Atey, 2017).
Since most used anesthetics produce unwanted effects in the
pediatric population, the quest for novel, safer anesthetics is one of
the most important and urgent tasks in the anesthesiology ﬁeld.
Every year, more than 4 million children are exposed to general
anesthetics due to diagnostic or surgical procedures. Since it has been
shown that common general anesthetics could be harmful to brain
development, triggering neurodegeneration and cognitive deﬁcits,
the US Food and Drug Administration (FDA) issued a warning
about the potentially neurotoxic effects of general anesthetics in
children (https://www.fda.gov/drugs/drug-safety-and-availability/
fda-drug-safety-communication-fda-review-results-newwarnings-about-using-general-anesthetics-and#:~:text=
%5B%2012%2D14%2D2016%20%5D,the%20development%
20of%20children’s%20brains). We previously reported that the
neurosteroid
analogue
(3β,5β,17β)-3-hydroxyandrostane-17carbonitrile (3β-OH) induces hypnosis in rat pups without
triggering neuronal apoptosis and acts as a thalamic CaV3.1 Ttype calcium channel (T-channel) blocker without having an
effect on the synaptic and extra-synaptic γ-aminobutyric acid A
(GABAA) receptors (Atluri et al., 2018; Timic Stamenic et al., 2021).
We also reported that 3β-OH blocks low-voltage-gated calcium
T-channels in the thalamic reticular nucleus (TRN), the central
medial nucleus of the thalamus (CMT), and the sensory neurons of
the dorsal root ganglion (DRG) (Todorovic et al., 2004; Joksovic et al.
, 2007; Timic Stamenic et al., 2021), but its effect on other voltagegated calcium channels remains unknown. Since it is well known
that most hypnotics and general anesthetics interact with multiple
targets, we sought to determine the additional mechanisms
underlying 3β-OH-induced hypnosis in mice.
The CaV2.3 isoform of voltage-gated R-type calcium
channels (R-type channels) (Soong et al., 1993) is
implicated in both presynaptic neurotransmitter release
and postsynaptic somatodendritic integration and longterm potentiation (Breustedt et al., 2003; Dietrich et al.,
2003; Kamp et al., 2005; Catterall, 2011). Similar to other
high-voltage-activated (HVA) calcium channels, R-type
channels not only contribute to neurotransmitter release
(Wu et al., 1998; Ricoy and Frerking, 2014) but are
involved in the regulation of neuronal excitability (Metz
et al., 2005; Zaman et al., 2011; Zamponi, 2016). Most of
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MATERIALS AND METHODS
Animals
Experimental procedures with animals were performed according to
the guidelines approved by the University of Colorado Anschutz
Medical Campus. The treatments of animals adhered to the
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recombinant HVA currents, a P/5 protocol was used for online leakage subtractions. HEK-293 cells were stably transfected
with both the α1E (CaV2.3) and β3 calcium channel subunits, as
described previously (Nakashima et al., 1998). Cells were typically
used 1–4 d after plating. The steps used to activate CaV2.3generated currents in HEK-293 cells in whole-cell experiments
were typically based on a holding potential (Vh) of −70 mV to test
potentials (Vt) at 0 mV.

guidelines set out in the NIH Guide for the Care and Use of
Laboratory Animals. All efforts were made to minimize animal
suffering and to use only the number of animals necessary to
produce reliable scientiﬁc data. Male juvenile and adult (postnatal
day (P), P35-50) wild-type (WT) and CaV2.3 knock-out (KO) mice
were used for ex vivo electrophysiological recordings, while older
male and female WT and CaV2.3 KO mice (3 months) were used for
behavioral and in vivo electrophysiological experiments. The
generation of the Cav2.3 null mutant (cacna1e, α1E null) and
WT littermates has previously been described in detail (Wilson
et al., 2000; Pereverzev et al., 2002; Weiergräber et al., 2006) and used
for all experiments. All animals were maintained on a 14/10 h
light–dark cycle with food and water ad libitum.

Ex Vivo Brain Slice Preparation
The WT and CaV2.3 KO mice were brieﬂy anesthetized with 5%
isoﬂurane and decapitated. Their brains were removed rapidly
and placed in a cold (4°C) oxygenated (95 vol% O2 and 5 vol%
CO2) solution. Live 250 μm-thick coronal brain slices were
sectioned at 4°C using a vibrating micro slicer in the same
cold solution (in mM): sucrose 260, D-glucose 10, NaHCO3
26, NaH2PO4 1.25, KCl 3, CaCl2 2, MgCl2 2(Laica VT 1200S).
Brain slices were immediately incubated for 30 min in the
following solution (in mM): NaCl 124, D-glucose 10, NaHCO3
26, NaH2PO4 1.25, KCl 4, CaCl2 2, MgCl2 2. This was carried out
at 37 °C before use in electrophysiology experiments, which were
carried out at room temperature. During incubation, the slices
were constantly perfused with a gas mixture of 95 vol% O2 and 5
vol% CO2.

Loss of Righting Reﬂex
LORR is commonly used to assess the depth of hypnosis in
animal models. LORR is assessed by placing the mouse on its back
until the animal loses its righting reﬂex. The criterion for the
LORR is the mouse’s failure to right itself twice within a 30 s
period. In addition, the mouse is considered to have regained its
righting reﬂex when it can right itself within a 30 s period. In
order to test the effect of 3β-OH on LORR, male and female WT
and CaV2.3 KO mice were injected intraperitoneally (i.p.) with
80 mg/kg of 3β-OH and LORR duration was analyzed. We chose
this dose based on our previous study, which showed that about
50% of WT mice exhibited LORR when injected with 80 mg/kg of
3β-OH i.p. (Timic Stamenic et al., 2021).

Electrophysiology Experiments in Brain
Slices
The external solution for current-clamp electrophysiology
experiments consisted of the following (in mM): NaCl 125,
D-glucose 25, NaHCO3 25, NaH2PO4 1.25, KCl 2.5, MgCl2 1,
CaCl2 2. For current-clamp experiments, the external solution
contained the synaptic blockers picrotoxin (20 μM), D-2-amino5-phosphonovalerate (D-AP5; 50 μM), and 2,3-dihydroxy-6nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione
(NBQX;
5 μM). The internal solution used for the current-clamp
recordings consisted of the following (in mM): potassiumD-gluconate
130,
ethylene-glycol-bis(β-aminoethylether)
N,N,N′,N′-tetraacetic acid (EGTA) 5, NaCl 4, CaCl2 0.5,
HEPES 10, Mg ATP 2, Tris GTP 0.5, pH 7.2.
Whole-cell recordings were performed in CMT neurons
visualized using Zeiss optics (Zeiss AXIO Examiner D1, ×40
objective). Glass microelectrodes (Sutter Instruments,
borosilicate glass with ﬁlament OD 1.2 mm) were pulled
using a Sutter Instruments P-1000 model and fabricated to
maintain an initial resistance of 3–6 mΩ. Neuronal membrane
responses were recorded using a Multiclamp 700 B ampliﬁer
(Molecular Devices, Foster City, CA, United States). Voltage
current commands and the digitization of the resulting
voltages and currents were performed with the Clampex 8.3
software (Molecular Devices) running on a PC-compatible
computer. Resulting current traces were analyzed using
Clampﬁt 10.5 (Molecular Devices). Statistical and graphical
analyses were performed using the GraphPad Prism 9.0
software (GraphPad Software) or Origin 7.0 (OriginLab).
Results are typically presented as means ± SEM unless
stated otherwise.

Ribonucleic Acid Extraction and
Quantitative Polymerase Chain Reaction
Animals were euthanized with isoﬂurane and their tissue (whole
thalamus or CMT punches) was collected. In order to obtain a higher
yield of RNA, punched samples of CMT were pooled from three
animals per group. RNA was extracted using the RNeasy mini kit
(Qiagen) according to the manufacturer’s protocol. RNA purity was
checked using the NanoDrop Spectrophotometer, OneC (Thermo
Fisher Scientiﬁc). For each sample, 50 ng of pure RNA was used to
synthesize cDNA based on the instructions for the iScript Advance
cDNA kit (BioRad) over four cycles: 25°C for 5 min, 46°C for 30 min,
95°C for 5 min, and 4°C for 30 min qPCR was performed for all
samples using TaqMan gene expression assay (probes: cacna1eMm00494444_m1; gapdh- Mm99999915_g1; all probes were
obtained from Thermo Fisher Scientiﬁc). The level of expression
of cacna1e was normalized to the housekeeping gene (gapdh) based
on formula 2^(-ΔCq) for all samples.

HEK-293 Cells
For recordings of CaV2.3 high-voltage-activated (HVA) calcium
current in HEK-293 recombinant cells, we used internal solution
containing
110 mM
Cs-methane
sulfonate,
14 mM
phosphocreatine, 10 mM HEPES, 9 mM EGTA, 5 mM
MgATP, and 0.3 mM Tris-GTP, with the pH adjusted to
7.15–7.20 with CsOH. The external solution used to record
recombinant CaV2.3 calcium currents contained 2 mM BaCl2,
152 mM TEA-Cl, and 10 mM HEPES adjusted to pH 7.4 with
TEA-OH. In most experiments, during recordings of
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Current-Clamp Experiments

conformation were obtained using a bright-ﬁeld Zeiss stereoscope
and the Zen Blue software.

Both stimulated tonic and burst ﬁring properties of CMT neurons
were characterized using multistep protocols in WT and CaV2.3
KO mice. To investigate the stimulated tonic ﬁring patterns in
CMT cells, we injected a depolarizing current pulse through the
recording pipette with a 400 ms duration in 25 pA incremental
steps starting from 50 pA. To investigate rebound burst ﬁring
patterns, the neurons were injected with hyperpolarizing currents
in 25 pA intervals from 0 to −225 pA. Subsequent stimulated
tonic action potential (AP) frequencies, rebound burst ﬁring
thresholds, AP in rebound burst, and input resistances (IR)
were determined. The resting membrane potential (RMP) was
measured at the beginning of each recording and not corrected
for the liquid junction potential.

Drugs
Isoﬂurane was purchased from McKesson (San Francisco, CA)
and 2-hydroxypropyl-β-cyclodextrin solution was purchased
from Santa Cruz Biotechnology (Dallas, TX). Ketamine and
Banamine (Merck) were obtained from the pharmacy. All the
other compounds were purchased from Sigma Chemical (St.
Louis, MO). The 3β-OH was synthetized by the Doug Covey
lab (Washington University School of Medicine, Saint
Louis, MO, United States), as described elsewhere (Atluri
et al., 2018). Neurosteroid 3β-OH was prepared as a
3 mM stock solution in dimethylsulfoxide (DMSO) for
electrophysiological experiments; aliquots were stored at −20°C
and diluted for use at a ﬁnal concentration of 3 μM, which was
delivered with a gravity-driven perfusion system. For EEG
recordings and behavioral experiments, 3β-OH was dissolved
in 25% of 2-hydroxypropyl-β-cyclodextrin solution and
injected i.p.

®

Electroencephalogram and Local Field
Potential Data Acquisition and Spectral
Analysis
Synchronized, time-locked video and EEG and local ﬁeld
potential (LFP) signals were recorded using the Pinnacle
system (Pinnacle Technology Inc., Lawrence, KS,
United States). The LFP signals were ampliﬁed (100x) and
digitized at a sampling frequency rate of 2000 Hz (high-pass
ﬁlter 0.5 Hz and low-pass ﬁlter 500 Hz) and stored on a hard
disk for ofﬂine analysis. The electrodes (one depth-coated
tungsten in CMT (anteroposterior–AP: −1.35 mm;
mediolateral–MD: 0; and dorsoventral–DV: −3.6 mm) and
two screw-type cortical (AP: −1 mm; MD: ± 3 mm; DV: 0))
were implanted under continuous 1–1.5% isoﬂurane
anesthesia. A screw electrode placed behind the lambda on
each side of the midline served as the ground (right) and
reference (left). Banamine - Merck (i.p. 2.5 mg/kg) was
applied right after surgery and every 24 h for 48 h. Seven to
10 days after surgery, mice of both strains (9 WT and 7
CaV2.3 KO) were put in a recording chamber and EEG
was recorded 15 min before the i.p. application of vehicle
(25% 2-hydroxypropyl-β-cyclodextrin) or 80 mg/kg of
3β-OH as baseline recordings. EEG was recorded for
60 min under vehicle and under 80 mg/kg of 3β-OH.
Although the LFP from CMT was recorded in all our in vivo
experiments, only cortical EEG waveforms were analyzed for
this study.
To compare spectra, 5 min of signal under 80 mg/kg of 3β-OH
were extracted 60 min after 3β-OH injection. All spectral analyses
were carried out using the and LabChart 8 and Origin 2018 software.
The relative (%) power was calculated for different frequency ranges:
δ (0.5–4 Hz), θ (4–8 Hz), α (8–13 Hz), β (13–30 Hz), and low γ
(30–50 Hz).
After the completion of the experiments, mice were anesthetized
with ketamine (100 mg/kg) and electrolytic lesions were made by
passing 5 μA of current for 1 s (5 times). Mice were additionally
anesthetized with isoﬂurane and perfused with ice-cold 0.1 M
phosphate buffer containing 1% of potassium-ferrocyanide. The
brains were extracted, kept in 4% paraformaldehyde (PFA) for
2 days, and sliced (100–150 μm) using a vibrating micro slicer
(Leica VT 1200S). Images of coronal slices for electrode location

Data Analysis
In every ex vivo experiment, we attempted to obtain as many
neurons as possible from each animal in order to minimize the
number of animals used. Statistical analysis was performed using
a two-way repeated measures (RM) ANOVA (in slice
electrophysiology experiments, both factors were repeated) as
well as Student’s unpaired and paired two-tailed t-tests where
appropriate. Signiﬁcance was accepted with p values <0.05.
Statistical and graphical analyses were performed using
the GraphPad Prism 9.0 software (GraphPad Software, La
Jolla, CA, United States) and Origin 2018 (OriginLab,
Northampton, MA, United States). All the EEG recordings
were analyzed using LabChart 8 (ADInstruments, Dunedin,
New Zealand).

®
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RESULTS
Reversible Inhibition of Recombinant
Human CaV2.3 Currents by 3β-OH

We previously reported that 3 μM of 3β-OH inhibits T-currents
in the rat TRN and CMT neurons in a voltage-dependent manner
(Joksovic et al., 2007; Timic Stamenic et al., 2021), but its effect on
R-type channels has not previously been studied. Hence, we ﬁrst
examined the effects of 3β-OH on isolated CaV2.3 R-type currents
in stably transfected HEK cells. Since we already investigated the
effects of 3 μM 3β-OH on native neuronal CaV3.1 T-channels and
excitability (Timic Stamenic et al., 2021), here we wanted to
explore effect of 3β-OH on recombinant R-type calcium channels
using the same approach. In addition, we previously reported that
3 μM of 3β-OH is an IC50 for T-type calcium currents (Joksovic
et al., 2007). Finally, our pharmacokinetic study in rats
demonstrated that a concentration of 3 μM can be achieved in
the brain during hypnosis with 3β-OH (Atluri et al., 2018).
Therefore, we used 3 μM of 3β-OH for our in vitro/ex vivo
electrophysiological recordings as a clinically relevant brain
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selective R-type channel inhibitor (Newcomb et al., 1998, 2000;
Bourinet et al., 2001). Representative traces of APs before (black)
and after SNX-482 (orange) application are shown in Figure 2B.
We noticed that the applications of SNX-482 in multiple neurons
signiﬁcantly decreased the averaged stimulated tonic ﬁring
(Figure 2C) and increased the rebound burst ﬁring threshold
(Figure 2E), but did not signiﬁcantly decrease the AP in
rebound burst ﬁring (Figure 2F). Representative traces of
rebound burst ﬁring in control conditions (black) and after
SNX-482 (orange) are presented in Figure 2D. The RMP values
did not differ before and after the drug application (mean ± SEM:
−62.88 ± 1.27 mV in control group; −65.48 ± 2.26 mV after SNX482 perfusion). Similarly, the values of input resistance (IR) at
100 pA current injection were not different between two groups
(mean ± SEM: 306.9 ± 60.51 MΩ; 270.10 ± 50.81 MΩ, control and
SNX-482 group, respectively).
FIGURE 1 | Inhibition of recombinant CaV2.3 R-type current in HEK cells
after bath application of 3β-OH. (A) Representative barium currents in control
conditions before drug application (black), during the perfusion of 3 μM 3β-OH
(green), and after drug washout (black). (B) Graph shows time course of
reversible CaV2.3 current amplitude reduction during the application of 3βOH. (C) Bar graph shows the percentage of R-type current reduction during
the perfusion of 3β-OH, which was averaged from multiple cells (n = 5, paired
two-tailed t-test, p < 0.05).

The 3β-OH Reduced Stimulated Tonic and
Rebound Burst Firing in Central Medial
Nucleus of the Thalamus Neurons in the
Wild-Type Mice More Profoundly Than in
Mutant Mice
Since we demonstrated the inhibitory effect of selective R-type
channel blocker SNX-482 on the CMT neurons’ excitability, we
next examined the effect of 3 μM of 3β-OH on the stimulated
tonic- and rebound burst ﬁring mode of CMT neurons in WT
and CaV2.3 KO mice. We found that 3β-OH signiﬁcantly reduced
the frequency of APs over a wide range of current injections
during the input–output protocols that we used to examine
stimulated tonic ﬁring mode in WT mice (Figure 3A, left).
For example, 3β-OH strongly inhibited ﬁring frequency by
about 33% after a current injection of 150 pA (Figure 3A
right). In contrast, although 3β-OH reduced the overall
stimulated tonic ﬁring frequency as measured by the inputoutput curves in the mutant mice to a smaller extent
(Figure 3E left), it failed to signiﬁcantly reduce the ﬁring
frequency elicited by a 150 pA current injection (Figure 3E
right). Importantly, the normalized averaged frequency
reduction across all current injections with 3β-OH was higher
in WT (42.38%) in comparison to CaV2.3 KO animals (mean
value −1.44%, Figure 3F). In both WT and mutant animals, 3βOH failed to lower the rebound burst ﬁring threshold, though it
did decrease the average AP number in the WT (Figures 3B,C)
but not in the mutant animals (Figures 3G,H). Representative
traces of rebound burst ﬁring in the control conditions (black)
and after 3β-OH application (green) recorded from WT animals
are presented in Figure 3D. Representative traces of the rebound
burst ﬁring in control conditions (blue) and after 3β-OH
application (purple) recorded from mutant mice are presented
in Figure 3I. Furthermore, 3β-OH did not signiﬁcantly affect the
RMP or IR of the CMT neurons in WT mice or mice lacking a
CaV2.3 channel (data not shown).
In order to independently validate our ﬁndings with mutant
animals, we next performed current-clamp recordings in CMT
slices of the WT mice pretreated with 0.5 μM of SNX-482
(Supplementary Figure S1). The stimulated tonic ﬁring slightly

concentration in order to compare our new results with those of
our previous studies. Representative barium current traces are
presented in Figure 1A. Black traces are inward barium currents
under control conditions and wash; green traces are from the
same cell in the presence of 3 μM of 3β-OH. The time course of
the current inhibition and the average data show that the addition
of 3β-OH to the external solution reversibly reduced the R-type
current by about 40% from the pre-drug baseline (Figures 1B,C,
respectively).

Selective Inhibition of R-type Currents by
SNX-482 Reduced Tonic and Rebound
Burst Firing in the Central Medial Nucleus of
the Thalamus Neurons of Wild-Type Mice
Since previous studies only investigated the expression of the
cacna1e gene in the whole thalamus, we used qPCR to assess
CaV2.3 expression in the CMT speciﬁcally. The top of Figure 2A
shows a scheme of the coronal section of the rodent brain with the
position of CMT (red dot), while the bottom of Figure 2A shows a
summary graph of our qPCR experiments. Our data are consistent
with the notion that mRNA for CaV2.3 is signiﬁcantly expressed in
the whole thalamus and CMT in WT mice and completely absent
from control experiments using tissue from KO animals. The role
of R-type channels in synaptic transmission has been thoroughly
studied; however, to the best of our knowledge, the role of these
channels in different ﬁring modes in CMT has never been
demonstrated before. Hence, we next examined the effects of
the use of 0.5 μM of SNX-482 on the output of CMT neurons
using current-clamp recordings from acute brain slices in WT
animals. This peptide was isolated from the venom of the African
tarantula, Hysterocrates gigas, and identiﬁed as a potent and
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FIGURE 2 | Stimulated tonic and rebound burst ﬁring was reduced in thalamic neurons during the application of SNX-482 in WT animals. (A) Schematic
presentation of CMT and qPCR data from the whole thalamus (WT and CaV2.3 KO mice, N = 4 and 4, respectively) and CMT (WT animals, N = 3, technical
replicate presented). (B) Representative traces of CMT action potential ﬁring before (black) and during the application of 0.5 μM of SNX-482 (orange) recorded
at an RMP of −60 mV. (C) Average frequency of stimulated tonic ﬁring mode before and after the perfusion of SNX-482 (n = 5, two-way RM ANOVA:
interaction F 5,20 = 3.44, p = 0.021; SNX-482 F 1,4 = 7.46, p = 0.052; current injection F 5,20 = 40.73, p < 0.001, Šídák’s multiple comparisons test presented). (D)
Representative traces of rebound burst ﬁring before (black) and during the application of SNX-482 (orange) in the same CMT neuron; note that with the same
current injection, there is no rebound burst ﬁring after SNX-482 perfusion. (E) Rebound burst ﬁring threshold after the hyperpolarization of the CMT neurons
before and during the application of SNX-482 (n = 5, paired two-tailed t-test, t4 = 3.49, p = 0.025). (F) Average numbers of AP in rebound burst ﬁring in control
and after SNX-482 (n = 5, paired two-tailed t-test, t4 = 2.265, p = 0.086). *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 3 | Stimulated tonic and rebound burst ﬁring of CMT neurons were reduced in the WT group more profoundly than in the CaV2.3 KO animals during the
application of 3β-OH. (A) Average stimulated tonic frequency ﬁring before (black) and during the application of 3 μM 3β-OH (green) across different current injection levels
(50–175 pA) in thalamic slices from WT animals (n = 6, two-way RM ANOVA: interaction F5,25 = 3.40, p = 0.018; 3β-OH F1,5 = 10.27, p = 0.024; current injection F5,25 =
13.49, p < 0.001, Šídák’s multiple comparisons test presented), left; average tonic ﬁring frequency at 150 pA current injection extracted from the same experiments
(n = 6, paired two-tailed t-test t5 = 2.60, p = 0.048), right. (B) Rebound burst ﬁring threshold after the hyperpolarization of the CMT neurons before and during the
application of the neurosteroid in WT mice (n = 6, paired two-tailed t-test, t5 = 1.85, p = 0.124). (C) Average numbers of APs in rebound burst ﬁring in control conditions
and during the administration of 3β-OH in WT mice (n = 6, paired two-tailed t-test, t5 = 5.38, p = 0.003). (D) Representative traces of rebound burst ﬁring before (black)
(Continued )
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FIGURE 3 | and during the application of 3β-OH (green) in a WT mouse. Note that with the same current injection, there is no rebound burst ﬁring after the perfusion of 3βOH. (E) The average tonic ﬁring frequency before (blue) and during the application of 3 μM of 3β-OH (purple) across different current injection (50–175 pA) in thalamic
slices from CaV2.3 KO animals (n = 7, two-way RM ANOVA: interaction F5,30 = 0.87, p = 0.510; 3β-OH F1,6 = 9.22, p = 0.023; current injection F5,30 = 42.80, p < 0.001),
left panel. The average tonic frequency at 150 pA current injections from the same experiment (n = 7, paired two-tailed t-test t6 = 1.44, p = 0.199), right panel. (F) Average
cumulative reduction in stimulated tonic ﬁring normalized to baseline (%) in WT (n = 6) and CaV2.3 KO (n = 7) animals, unpaired two-tailed t-test t11 = 2.21, p = 0.049. (G)
Rebound burst ﬁring threshold after the hyperpolarization of the CMT neurons in CaV2.3 KO mice (n = 7, paired two-tailed t-test, t6 = 1.40, p = 0.210). (H) Average
number of APs in rebound burst ﬁring in control conditions and during the administration of 3β-OH in CaV2.3 KO mice (n = 7, paired two-tailed t-test, t6 = 1.99, p = 0.093).
(I) Representative traces of rebound burst ﬁring before (blue trace) and during the application of 3β-OH (purple trace) in a CaV2.3 KO mouse; note that with the same
current injection, 3β-OH failed to abolish rebound burst ﬁring. *p < 0.05, **p < 0.01, ***p < 0.001.

for the hypnotic effect of this neurosteroid in vivo. We used an
assay of LORR as a measure of the hypnotic potency of the drug,
which was injected systemically into WT and mutant mice of
both sexes. When mice were injected with 80 mg/kg of 3β-OH
i.p., we observed sex differences in both WT and CaV2.3 KO
animals (Figure 4A), where females were more sensitive to the
neurosteroid effect in comparison to males. For example, the
average duration of LORR was about 3-fold longer in females in
comparison to males in both WT and mutant cohorts.
Importantly, the duration of LORR was about 25% longer in
the WT group of animals in comparison to CaV2.3 KO mice,
indicating that mutant mice are relatively resistant to
neurosteroid-induced hypnosis.
FIGURE 4 | Sex- and genotype-dependent resistance to hypnosis
measured by LORR in the CaV2.3 KO mice when compared to the WT
littermates after i.p. injections of 80 mg/kg 3β-OH. (A) Left, schematic
presentation of LORR experiment; right, average duration of LORR after
injections of 3β-OH (two-way ANOVA: interaction F1,51 = 0.99, p = 0.320;
genotype F1,51 = 5.15, p = 0.027; sex F1,51 = 112.00, p < 0.001). N = 13–14
animals in WT group; N = 13–14 animals in CaV2.3 KO group, *p < 0.05, ***p <
0.001.

Electroencephalogram Recordings
Demonstrate Signiﬁcant Oscillatory
Differences Between WT and CaV2.3 KO
Mice During 3β-OH-Induced
Unconsciousness in Female and Male
Animals
We next tested the hypothesis that CaV2.3 channels may have an
effect on the 3β-OH-induced thalamocortical rhythmic
oscillations. We used cortical EEG recordings in WT and
CaV2.3 KO mice to investigate if CaV2.3 channels are
important for oscillations in vivo during systemic
administration of 80 mg/kg 3β-OH in female and male mice.
After the injection of 80 mg/kg of 3β-OH i.p., we noticed a
transient rise (5–10 min after neurosteroid injection) in total
power in all analyzed frequencies followed by a global EEG
reduction in all groups except male mutant mice (Figure 5).
During analyzed period of 60 min, we observed statistically
signiﬁcant differences between WT and mutant male animals
in all oscillations (Figures 5A–E right, horizontal line). Although
differences were statistically signiﬁcant only for oscillations in the
α, β and low γ bands (Figures 5C–E left), WT female animals
showed more EEG reduction in comparison to mutant females
during 60 min of recordings following injections of 3β-OH. We
did not observed baseline differences in any of the tested
frequencies between the groups.
Next, we performed a detailed analysis of oscillatory
differences in vivo between WT and CaV2.3 KO female and
male animals 60 min after i.p. injections of 80 mg/kg of 3βOH (Figures 6, 7, respectively). Representative cortical
spectrograms under baseline conditions and after the
administration of 3β-OH recorded from WT and CaV2.3 KO
female mice with representative EEG traces are presented in

decreased after the perfusion of 3β-OH (Supplementary Figure S1A
left), similarly to in CaV2.3 KO animals (Figure 3A), with no
signiﬁcant effect on average tonic ﬁring at 150 pA (Supplementary
Figure S1A right). The average normalized frequency reduction
achieved with 3β-OH recorded from untreated CMT neurons
from WT mice, untreated CaV2.3 KO animals, and WT mice with
the addition of SNX-482 in the external solution are summarized in
Figure S1B. The rebound burst ﬁring threshold was not altered after
3β-OH perfusion (data not shown) and the average number of AP in
rebound burst ﬁring was not altered either (Supplementary Figure
S1C). Additionally, we compared the baseline excitability of CMT
neurons (stimulated tonic ﬁring) in WT and CaV2.3 KO animals and
did not ﬁnd any statistically signiﬁcant difference between the two
groups (data not shown), which could be due to compensatory
changes in global KO animals. Importantly, we conclude that the
pharmacological inhibition of the CaV2.3 channel in WT mice largely
diminishes the effects of 3β-OH on spike ﬁring in CEM neurons,
similar to the genetic deletion of this channel.

The CaV2.3 Channels Are Important for
Neurosteroid-Induced Hypnosis
Since we observed differences in thalamic excitability after the
perfusion of 3β-OH in ex vivo slice recordings from WT and
mutant animals, we next asked if CaV2.3 channels are important
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FIGURE 5 | Total EEG power after i.p. injections of 80 mg/kg of 3β-OH during the time course of 60 min in WT (black, baseline; green, 3β-OH) and CaV2.3 KO (blue,
baseline; purple, 3β-OH) animals in the females is depicted on the left; in the males, this is presented on the right. Total δ (A), θ (B), α (C), β (D), and low γ (E) power after
3β-OH injection in females and males. (A) Left, two-way RM ANOVA: interaction F11,88 = 0.60, p = 0.823; genotype F1,8 = 3.39, p = 0.103; time F11,88 = 15.72, p < 0.001.
(B) Left, two-way RM ANOVA: interaction F11,88 = 0.72, p = 0.715; genotype F1,8 = 4.57, p = 0.065; time F11,88 = 31.56, p < 0.001. (C) Left, two-way RM ANOVA:
interaction F11,88 = 0.48, p = 0.910; genotype F1,8 = 6.64, p = 0.033; time F11,88 = 17.34, p < 0.001. (D) Left, two-way RM ANOVA: interaction F11,88 = 1.03, p = 0.430;
genotype F1,8 = 9.54, p = 0.015; time F11,88 = 5.54, p < 0.001. (E) Left, two-way RM ANOVA: interaction F11,88 = 1.82, p = 0.065; genotype F1,8 = 7.94, p = 0.022; time
(Continued )
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FIGURE 5 | F11,88 = 7.43, p < 0.001. (A) Right, two-way RM ANOVA: interaction F11,99 = 6.87, p < 0.001; genotype F1,9 = 7.05, p = 0.026; time F11,99 = 1.01, p = 0.443,
Šídák’s multiple comparisons test presented on Figure as a line. (B) Right, two-way RM ANOVA: interaction F11,99 = 6.73, p < 0.001; genotype F1,9 = 7.72, p = 0.021;
time F11,99 = 0.17, p = 0.999. Šídák’s multiple comparisons test presented as a solid black line. (C) Right, two-way RM ANOVA: interaction F11,99 = 6.85, p < 0.001;
genotype F1,9 = 5.33, p = 0.046; time F11,99 = 0.87, p = 0.576. Šídák’s multiple comparisons test presented in ﬁgure as a line. (D) Right, two-way RM ANOVA: interaction
F11,99 = 6.84, p < 0.001; genotype F1,9 = 6.25, p = 0.034; time F11,99 = 2.36, p = 0.012. Šídák’s multiple comparisons test presented in ﬁgure as a line. (E) Right, two-way
RM ANOVA: interaction F11,99 = 3.64, p < 0.001; genotype F1,9 = 12.93, p = 0.006; time F11,99 = 4.31, p < 0.001. Šídák’s multiple comparisons test presented in ﬁgure as
a line. N = 4-6 animals in WT group; N = 5–7 animals in CaV2.3 KO group.

Figures 6A,B. The analysis of the total and relative baseline
power did not show any differences between WT and mutant
animals (Figure 6C, left and right). Similarly, the analysis of total
power 60 min after neurosteroid injection did not reveal
differences between the two groups of animals (Figure 6D,
left). In contrast, the analysis of relative power after the
administration of 3β-OH revealed differences in the β
frequency range, with an increase in β oscillations in mutant
female mice of about 30% compared to the WT group (Figure 6C,
right).
Representative cortical spectrograms recorded from WT and
CaV2.3 KO male mice with representative EEG traces under
baseline conditions and 3β-OH are presented in Figures 7A,B.
The analysis of the total and relative baseline power did not show
differences between the WT and mutant animals (Figure 7C, left
and right). However, the analysis of total power recorded 60 min
after the injection of 3β-OH revealed a higher EEG power in θ, α,
and β oscillations in mutant male mice in comparison to WT
animals (Figure 7C, left). Additionally, the analysis of relative
power revealed a signiﬁcant rise in slow oscillations in the δ
frequency range in WT compared to CaV2.3 KO male mice
(Figure 7D, right).

tonic ﬁring in CMT neurons from CaV2.3 KO mice and CMT
neurons from WT mice that had been pretreated with SNX-482.
Since we previously reported the ability of 3β-OH to block CaV3.1
channels in CMT neurons (Timic Stamenic et al., 2021), the
reduction in excitability in mutant animals is also related to their
inhibitory effect on T-type calcium channels. Furthermore, the
existence of compensatory changes and the possible upregulation
of other VGCC (mostly T-type calcium channels) in CaV2.3
mutant mice cannot be excluded. However, previous studies
did not ﬁnd any change in the thalamic T-channel expression
levels in CaV2.3 KO animals in comparison to their WT
littermates (Weiergräber et al., 2006; Siwek et al., 2014).
Next, we examined the involvement of R-type channels in the
hypnotic effects of neurosteroids using i.p. injections of 80 mg/kg
of 3β-OH to produce LORR in WT and mutant animals of both
sexes. Sex differences from the CaV2.3 channel had been observed
earlier in the mice model of central sensitization, where CaV2.3
inhibition, especially in female mice, had a signiﬁcant effect
(Ferreira et al., 2021). Furthermore, sex differences were
demonstrated after the application of neuroactive steroids in a
variety of rodent models (Fink et al., 1982; Arenillas and Gomez
de Segura, 2018; Joksimovic et al., 2021). We recently reported the
sex-dependent hypnotic effect of 3β-OH in rats (Joksimovic et al.,
2021); thus, here, we conﬁrmed the sex-dependent effect of 3βOH in CaV2.3 KO and WT animals. Consistent with our rat
study, we found that female mice had longer LORR durations in
comparison to male animals. Importantly, WT animals were
more sensitive to 3β-OH-induced hypnosis than CaV2.3 KO
mice, strongly suggesting that the inhibition of CaV2.3
channels at least partly contributes to the hypnosis induced by
3β-OH in mice in both sexes.
It is known that the Cav2.3 channel activation requires the
use of a mid to high voltage range, which is higher than for
T-type calcium channels but lower than for other HVA
channels (Catterall et al., 2005). Hence, the activation of
these channels in thalamic neurons can facilitate the tonic
ﬁring mode and blockade can decrease the excitability and
alter the generation of thalamocortical oscillations. It is
known that many general anesthetics may generate
rhythmic oscillations of bursts with blackout sequences
(suppressions), and this burst-suppression pattern is
generally thought to correlate with the blockage of
thalamocortical sensory information (Steriade et al., 1994).
We previously demonstrated that presynaptic R-type
channels contribute to isoﬂurane-induced effects on
inhibitory synaptic transmission in NRT and cortical EEG

DISSCUSION
Here, we ﬁrst investigated the effects of 3β-OH on isolated
recombinant CaV2.3 R-type current expressed in HEK-293
cells. We found that the R-type current was reversibly reduced
by about 40% after the perfusion of 3 μM of 3β-OH, indicating the
ability of this neurosteroid to inhibit the CaV2.3 channel in a
relevant brain concentration during hypnosis, as determined by
LORR (Atluri et al., 2018). In order to further investigate the role
of R-type channels in CMT neuronal excitability, we performed
ex vivo electrophysiological recordings and found a reduction in
stimulated tonic ﬁring after the application of SNX-482, a
selective R-type channel inhibitor (Newcomb et al., 1998;
2000; Bourinet et al., 2001). Additionally, we found that the
threshold for rebound burst generation was increased after the
application of SNX-482, indicating the need for greater neuronal
hyperpolarization in order to generate rebound bursting when
R-type channels are blocked. Similarly, we studied the effect of
3β-OH on neuronal excitability in CMT in both WT and mutant
animals. Predictably, we found a profound reduction in tonic and
rebound burst ﬁring in CMT neurons from WT animals after the
administration of 3β-OH and a modest decrease in stimulated
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FIGURE 6 | The effects of 3β-OH on EEG in female WT and CaV2.3 KO animals at a time point of 60 min after i.p. injections of 80 mg/kg of 3β-OH. (A)
Representative baseline heat map from a female WT (top) and a CaV2.3 KO (bottom) animal with the representative EEG traces (WT, black; CaV2.3 KO, blue). (B)
Representative heat map from a female WT (top) and a CaV2.3 KO (bottom) animal with the representative EEG traces (WT, green; CaV2.3 KO, purple) at time point of
60 min after injections of 3β-OH. (C) Total power during baseline (left) and relative baseline power (right). (D) Total power (left) and relative power (right, two-way RM
ANOVA: interaction F4,32 = 2.90, p = 0.004; genotype F1,8 = 0.09, p = 0.771; frequency F4,32 = 16.44, p < 0.001. Šídák’s multiple comparisons test presented) at 60 min
after 3β-OH. N = 6 animals in WT group; N = 4 animals in CaV2.3 KO group, *p < 0.05.
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FIGURE 7 | The effects of 3β-OH on EEG in male WT and Ca V2.3 KO animals at the time point of 60 min after i.p. injections of 80 mg/kg of 3β-OH. (A)
Representative baseline heat map from a male WT (top) and a CaV2.3 KO (bottom) animal with the representative EEG traces (WT, black; Ca V2.3 KO, blue). (B)
Representative heat map from a male WT (top) and a Ca V2.3 KO (bottom) animal with the representative EEG traces (WT, green; Ca V2.3 KO, purple) 60 min after
3β-OH. (C) Total power during baseline (left) and relative baseline power (right). (D) Total power (left, two-way RM ANOVA: interaction F4,36 = 5.86, p =
0.001; genotype F 1,9 = 11.49, p = 0.008; frequency F 4,36 = 19.49, p < 0.001, Šídák’s multiple comparisons test presented) and relative power (left, two-way RM
ANOVA: interaction F4,36 = 2.09, p = 0.103; genotype F1,9 = 1.84, p = 0.208; frequency F4,36 = 61.56, p < 0.001, Šídák’s multiple comparisons test presented)
60 min after 3β-OH. N = 5 animals in WT group and N = 6 animals in CaV 2.3 KO group. *p < 0.05, **p < 0.01, ***p < 0.001.
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Interestingly, we did not observed baseline EEG differences
between the WT and CaV2.3 KO animals.
The inability of 3β-OH to block thalamic rebound bursting,
suppress EEG, and increase slow-frequency oscillation in
CaV2.3 KO male mice is likely to explain the inability of
the neurosteroid to effectively induce hypnosis in these
animals. The LORR and EEG changes observed in female
animals suggest the existence of the same neurosteroidinduced mechanisms in WT and mutant mice, with
stronger 3β-OH-induced hypnosis and EEG reduction seen
in female WT animals. The observed inhibitory effects on
stimulated tonic ﬁring in both mutant and control cohorts,
even though more prominent in WT mice, could also
implicate the involvement of the CaV3.1 channel, which
works in concert with the inhibition of the CaV2.3 channel
in the thalamus as a target for 3β-OH’s effects. However, it
appears that the reduced tonic excitability seen in many
mutant male animals could not effectively induce hypnosis.
Although the interpretation of behavioral studies using global
KO mice may be complicated due to possible compensatory
changes, our results achieved with CaV2.3 KO animals
strongly suggest that our approach is productive for
validating, for the ﬁrst time, the role of the R-type channel
in neurosteroid-induced hypnosis.

burst-suppression patterns (Joksovic et al., 2009).
Additionally, it has been demonstrated that CaV2.3deﬁcient mice have a reduced wake duration and increased
duration of slow-wave natural and urethane-induced sleep
(SWS) (Siwek et al., 2014). Thus, we performed detailed EEG
analyses after neurosteroid injection in adult CaV2.3 KO mice
and their WT littermates. Although i.p. injections of
neurosteroids rarely show the characteristic burstsuppression patterns of volatile anesthetics, we observed a
drastic reduction in EEG power predominantly in female WT
animals and a lack of EEG power reduction in mutant male
mice (Figures 5–7). It is not surprising that voltage-gated
calcium channels have relevance in sleep physiology and
epileptogenesis due to their unique electrophysiological
properties and cellular distribution (Talley et al., 1999; Lee
et al., 2004; Anderson et al., 2005; Weiergräber et al., 2008;
Siwek et al., 2014). Hence, we reasoned that CaV2.3 channels
might be involved in drug-induced hypnotic/anesthetic
effects. Recent studies have demonstrated the important
role of Ca V2.3 calcium channels in thalamocortical
rhythmicity (Weiergräber et al., 2006, 2008; Zaman et al.,
2011) and in septohippocampal synchronization associated
with θ oscillations (Müller et al., 2012). Over time, we showed
that there is a difference in total α, β, and low γ oscillations
between WT and CaV2.3 KO female animals, with a more
profound reduction in these frequencies seen in WT mice
after neurosteroid administration. A similar effect was seen in
the male mice, where 3β-OH showed the reduction of total
power in all analyzed frequencies in WT animals but failed to
do so in mutant males. Due to this, the differences in
neurosteroid effect seen in the EEG oscillations of WT and
KO male animals over time appeared more dramatic than
those in females.
Consistent with the observed effects on LORR in vivo, our
EEG recordings revealed different effects of 3β-OH in WT and
CaV2.3 KO mice, with the presence of a sex-dependent effect.
For example, the relative δ power 60 min after the application
of 3β-OH was higher in WT male mice compared to mutant
mice, reﬂecting the different behavioral states of the animals.
Additionally, the analysis of the total power under the
neurosteroid revealed the inability of the 3β-OH to
suppress EEG power in male mutant animals. On the
contrary, the total power at a time point of 60 min after
the application of 3β-OH did not differ between the
mutant and control female animals, but the relative power
showed a stronger increase in β oscillations in mutant
animals. The relative δ oscillations were somewhat higher
in WT than in mutant female mice, although this effect was
not signiﬁcant. It is well known that during light hypnotic/
sedative states, an increase in β oscillations is frequently seen,
and during deep hypnosis an increase in slow δ frequencies,
burst-suppression activity, and EEG reduction are present
(Stamenic and Todorovic, 2022). Hence, we posit that the
lower relative δ values in mutants and higher relative β power
in mutant females implied the inability of the neurosteroid to
induce a deeper hypnotic state in CaV2.3 KO mice.
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